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Abstract
Despite advancements in many areas of human medicine, infectious disease continues to
be a leading cause of morbidity and mortality worldwide.

Improper and excessive use of

antibacterial compounds has led to the rise of resistant species of bacteria like Methicillin
Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Enterococci (VRE), and Extreme
Drug Resistant Tuberculosis (XDR-TB). We have found a possible alternative that would replace
the current ineffective treatment methods – a potentially new class of antibiotics that inhibits
Gram-positive bacteria growth. These chemical compounds have shown inhibition against S.
aureus and E. faecalis, so MRSA and VRE strains were then tested. Inhibition by the newly
developed compounds was identical to their inhibition levels against non-resistant strains of both
species. These carboxylic amide compounds are novel, non-Penicillin based antibiotics, and could
be used to treat MRSA and other Gram-positive infections.

Introduction
Progress in the development of new antibiotics is tapering off, mostly because of recent
abandonment of natural products and infectious disease discovery programs by several large
pharmaceutical companies (Baltz, 2007). This declining interest comes at an inopportune time;
the rate of infections caused by bacteria that have acquired antibiotic resistance is higher than
ever. Strains like Methicillin Resistant Staphylococcus aureus (MRSA) and Vancomycin Resistant
Enterococci (VRE), are commonly acquired through a nosocomial infection. Bacteria acquire
resistance to antibiotics in a variety of ways, one of which is by transferring resistance genes from
one species of bacterium to another (Barlow, 2009). Novel antibiotics help prevent resistance
development in bacteria that stems from natural or synthetically derived sources. Most antibiotics
currently being utilized in human medicine are direct natural products or semi-synthetic
derivatives of the soil bacteria Actinomycetes (Baltz, 2007). Many studies searching for novel
compounds with antibiotic properties are underway, and the process continues to be at the
forefront of medical interest (Matijevic-Sosa, 2005).

Our approach to this problem was to synthesize novel compounds and test them for any
potential inhibitory effect against Gram-positive and Gram-negative bacteria. The compounds
tested were derivatives of a known telomerase inhibitor, GV-1, the structure of which is shown in
Figure 1. To date, there are no published studies of the effects of GV-1 against bacteria. Disk
Diffusion tests, along with tests for Minimum Inhibitory Concentration (MIC’s) where applicable,
were performed with each compound against Staphylococcus aureus and Escherichia coli. If a
compound demonstrated high effectiveness during initial phases of testing, it was also subject to
further testing for effectiveness against bacteria while in the presence of human serum.

Methods
GV-1 and any derivatives (Figure 1) were dissolved in 20%TEA at concentrations ranging
from 1.25 mg/ml to 10 mg/ml.

Two methods were used to test the possible inhibition of the

organisms by the compounds: the disk diffusion test, and the test for the minimum inhibitory
concentration (MIC). For the disk diffusion tests, 10ul of the compound was placed on sterile
paper disks. The disks were placed on top of “lawns” of overnight cultures of organisms and
allowed to grow for 18-24 hours. The disk diffusion method was used as the initial screen to
determine if any inhibition, signified by a zone of clearing (Figure 2), was provided by the
compound. If inhibition was present, then an MIC test was performed.
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Figure 1. Chemical Structure of GV-1 and a primary structure showing areas modified during
derivative synthesis.
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Figure 2. This figure depicts the initial six microorganisms that were sensitive to GV-1 in
previous tests. Zones of clearing around the discs are indicative of compound effectiveness.
Disk Diffusion Test of GV-1 against B. subtilis (A), M. leuteus (B), S. aureus (C), M. smegmatis (D),
S. epidermidis (E), and S. pneumoniae (F). Disk 1 is a negative control of 20% triethanolamine;
disk 7 is a positive control of 1mg/ml Ampicillin. Disks 2-6 have the following concentrations of
GV-1, respectively: 10, 7.5, 5, 2.5, and 1mg/ml.

Results
We tested over 25 derivatives of the primary GV-1 compound over the course of the
summer (see Table 1). Eight of the compounds tested showed high levels of potency against S.
aureus. Of those eight that were highly effective, two compounds were effective enough to
warrant further testing with human serum. Those test results showed that the serum bound to
both compounds, lowering their activity levels significantly.

Table 1. Zone of Inhibition (diameter) and MIC values against S. aureus for GV-1 and synthesized
derivatives are shown.
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Name
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Not
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Not
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Conclusions
Past research done on the primary GV-1 compound previously showed that it was effective
against eight Gram-positive and one acid fast species of microorganisms. This previous work also
showed that the MICs for the main GV-1 compound and derivatives were equally effective against
normal and resistant strains of bacteria. In this study we tested over 25 compounds that were
novel derivatives of the primary GV-1 compound, and several compounds showed promising
activity levels with MIC values of 4 or 8. Although some of the derivatives of GV-1 that we tested
exhibited increased activity levels when compared to the primary compound, these activity levels
decreased significantly when human serum was included in the testing. Our ultimate goal is that
these antimicrobials could be developed further and eventually used to treat MRSA and other
Gram-positive infections.
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